We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Biotech & pharma: unique business in history- Dr. Radi Haloub
-
2. Environmental aspects and changes in health systems
- Dr. Radi Haloub
-
3. Why do pharmaceutical companies exist?
- Dr. Radi Haloub
-
4. Capability and capacity of pharmaceutical business
- Dr. Radi Haloub
-
5. Culture and structure in the pharmaceutical industry- Dr. Radi Haloub
-
6. Corporate responsibility and governance in pharmaceutical companies: responsible profits- Dr. Radi Haloub
-
7. Overseas and beyond in pharmaceutical business- Dr. Radi Haloub
-
8. Future technologies in biotech and pharmaceutical companies- Dr. Radi Haloub
-
9. Mergers and acquisitions in the pharmaceutical industry- Dr. Radi Haloub
Printable Handouts
Navigable Slide Index
This material is restricted to subscribers.
Topics Covered
- Firm and environment strategy
- Resource allocation and capability
- Business environment layers
- Impact of change on pharmaceutical firms
- Competitor and customer evaluation
- Transition and change assessment
Links
Series:
Categories:
Talk Citation
Haloub, R. (2025, October 30). Environmental aspects and changes in health systems [Video file]. In The Business & Management Collection, Henry Stewart Talks. Retrieved November 24, 2025, from https://doi.org/10.69645/RSJC4682.Export Citation (RIS)
Publication History
- Published on October 30, 2025
A selection of talks on Strategy
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, everyone.
This is the second session about
the pharmaceutical industry
and environmental aspects.
My name is Radi Haloub,
I am an associate professor
and program leader for
Biotech and Pharmaceutical
Management at
UCL Global Business School
for Health in London.
0:19
In this session, I'm
going to talk about
the pharmaceutical industry
and the environmental aspects
on the changes on health systems
and how these changes will have
an impact on the
pharmaceutical business.
It is very important
to remember that
the environment will always
affect the industries,
not only pharmaceuticals
and biotech,
but because this is
a unique industry,
sometimes these changes
can be unpredicted,
very uncertain and
cannot be controlled.
For example, COVID-19 was
not predicted in 2019,
but it became a fact
and a challenge to
pharmaceutical and
biotech industries.
Also, the changes
that the governments
introduced in order
to accelerate
the registration of
the COVID vaccine
can be a case study to use
to speed up the adaptation
of healthcare environment
in the future.
1:13
In this slide, we look at
the firm in terms of who we are,
what is the purpose of the
existence of our business,
and what do we have in terms
of resources and competencies.
And the structure
and systems in place
that we have in this firm.
The first analysis
that we have to do
is to look at the
firm themselves
and look at the
representatives in
the pharmaceutical
and biotech industry,
and to see why we do exist
and how these are going to
affect us in the future.
I put there the strategy
is all about fit.
How this firm is going to
fit within the environment
and the uncontrolled changes
within the environment?
Of course, there are factors
relevant to the
speed of adaptation,
the ability of the firm
to change their resources
and to allocate competencies
in the right direction
based on the changes
within the environment.
But it's always the
question of who we are,
and what's the purpose,
and what do we
have in terms of resources and
competencies and the structure
we offered in the
pharmaceutical firm.